Navigation Links
Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
Date:12/8/2009

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that it will be presenting six studies focusing on MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium (SABCS), one of the premiere conferences in breast cancer research worldwide. The SABCS will take place December 9-13, at the Henry B. Gonzalez Convention Center in San Antonio, Texas, USA.

Agendia's studies to be presented at the SABCS further establish the broad predictive and prognostic power of MammaPrint, the only FDA-cleared breast cancer recurrence test available to patients and physicians. Conference attendees can meet the Agendia team at booth #556.

    Study results will be discussed at the following sessions:
    Date: Thursday, December 10, 2009
    Time: 5:30 pm - 7:30 pm
    Poster presentation (102)

Combining Genomic Profiling (70 Gene-MammaPrint) with Nodal Status Allows to Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies

Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I, Delaloge S, van 't Veer L. Institut Gustave Roussy, Villejuif, France; Netherlands Cancer Institute, Amsterdam, The Netherlands; European Institute of Oncology, Milan, Italy; Agendia BV, Amsterdam, The Netherlands.

Date: Friday, December 11, 2009

Time: 7 am - 9 am

Poster presentation (2026)

Basal-, Luminal-, and HER2- Molecular Subtype, and the MammaPrint 70-Gene Signature as Predictors of Response to Neoadjuvant Chemotherapy (NCT) with Docetaxel, Doxorubicin, Cyclophosphamide (TAC), or AC and Nab-Paclitaxel and Carboplatin +/- Trastuzumab in Patients (pts) with Stage II-III and Inflammatory Breast Cancer (BC)

Somlo G, Lau S, Frankel P, Garberoglio C, Kruper L, Yen Y, Luu T, Hurria A, Chung CT, Mortimer J, Yim J, Paz IBe, Krijgsman O, Delahaye L, Stork-Sloots L, Bender R. City of Hope Comprehensive Cancer Center, Duarte, CA; Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA.

Date: Saturday, December 12, 2009

Time: 7 am - 9 am

Poster presentation (4049)

The 70-Gene Profile (MammaPrint) Is an Independent Predictor of Breast Cancer Specific Survival for Women 65 Years of Age or Older

Bedard PL, Mook S, Knauer M, Durbecq V, Bernard-Marty C, Glas AM, Cardoso F, van 't Veer LJ. Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, The Netherlands; TRANSBIG Consortium, Brussels, Belgium; Agendia BV, Amsterdam, The Netherlands

    Date: Sunday, December 13, 2009
    Time: 7 am - 8:30am
    Poster presentation (6131)
    Molecular Subtype Profile Reveals Therapy Predictive Power

de Snoo FA, Krijgsman O, Roepman P, Bender RA, Glas AM. Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA..

Date: Sunday, December 13, 2009

Time: 7 am - 8:30am

Poster presentation (6146)

Biological Functions of Genes in the 70-Gene MammaPrint Tumor Expression Profile Reflect Molecular Mechanism of Tumor Metastasis

Glas AM, Tian S, Roepman P, Krijgsman O, Van 't Veer LJ, de Snoo F. Agendia BV, Amsterdam, The Netherlands; The Netherlands Cancer Institute, Amsterdam, The Netherlands.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets three products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

SOURCE Agendia B.V.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
2. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
3. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
4. Time Magazine Names Agendia Test a Best Invention of 2007
5. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans
8. Hospice Foundation of America Presents Webinar on Bereavement Camps for Kids: Benefits and Challenges
9. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
10. Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference
11. Makers of Powerful Painkillers Present Safety Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... patients on early orthodontic treatment and accepting new pediatric patients, with or without a ... help young patients have a better orthodontic outcome and experience. When patients receive early ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition ... report to their offering. ... The ablation device global market is expected to ... 2023. Ablation is the minimally invasive therapeutic tissue ... or diseased tissue removal, to the removal of abnormally conducting cardiac ...
(Date:3/29/2017)... March 29, 2017  NuVasive, Inc. (NASDAQ: NUVA), ... spine surgery with minimally disruptive, procedurally-integrated solutions, today ... clearance of the CoRoent® Small Interbody™ System indicated ... in the cervical spine. This marks the first ... used at up to four contiguous levels. ...
(Date:3/29/2017)... KALAMAZOO, Michigan , USA, March 29, 2017 /PRNewswire/ ... a Company that Cares by People magazine, in partnership ... out of 50 companies on the list. This list ... employees that have succeeded in business while also demonstrating ... and the environment.  To determine the ...
Breaking Medicine Technology: